Therefore, we characterized the potential of DIACC3010 to treat human GC by employing both in vitro and in vivo preclinical models and investigated how the preclinical efficacy of DIACC3010, alone and combined with trastuzumab, correlated with known (PIK3CA mutations18 and pERK expression19) and potential biomarkers of sensitivity and resistance to PAM pathway inhibition. Here, PIK3CA is linked to gastric cancer.